Use of Ozone-Depleting Substances:
Federal Register: September 17, 2010 (Volume 75, Number 180)
Rules and Regulations
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration 21 CFR Part 2
Docket No. FDA-2006-N-0304
(formerly Docket No. 2006N-0262)
Use of Ozone-Depleting Substances; Removal of Essential-Use
Designation (Flunisolide, etc.); Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; correction.
SUMMARY: The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone- depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers
(MDIs). The document was published with an inadvertent error. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Diane Sullivan, Office of Policy,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171.
SUPPLEMENTARY INFORMATION: In FR Doc. 2010-8467, appearing on page 19213, in the Federal Register of Wednesday, April 14, 2010, the following correction is made: 1. On page 19213, in the third column, the heading ``RIN 0910-
AF92'' is corrected to read ``RIN 0910-AF93''.
Dated: September 13, 2010.
Acting Deputy Commissioner for Policy, Planning and Budget.
FR Doc. 2010-23195 Filed 9-16-10; 8:45 am
BILLING CODE 4160-01-S